Please use this identifier to cite or link to this item: https://repositorio.ufpa.br/jspui/handle/2011/2420
Full metadata record
DC FieldValueLanguage
dc.creatorFERREIRA, Michelli Erica Souza-
dc.creatorGOMES, Margarete do Socorro Mendonça-
dc.creatorVIEIRA, José Luiz Fernandes-
dc.date.accessioned2011-12-14T14:21:01Z-
dc.date.available2011-12-14T14:21:01Z-
dc.date.issued2011-02-
dc.identifier.citationFERREIRA, Michelli Erica Souza; GOMES, Margarete do Socorro Mendonça; VIEIRA, José Luiz Fernandes. Metemoglobinemia em pacientes com malária por Plasmodium vivax em uso oral de primaquina. Revista da Sociedade Brasileira de Medicina Tropical, Uberaba, v. 44, n. 1, p. 113-115, jan./fev. 2011. Disponível em: <http://www.scielo.br/pdf/rsbmt/v44n1/26.pdf>. Acesso em: 14 dez. 2011. http://dx.doi.org/10.1590/S0037-86822011000100026.pt_BR
dc.identifier.issn0037-8682-
dc.identifier.issn1678-9849-
dc.identifier.urihttp://www.repositorio.ufpa.br:8080/jspui/handle/2011/2420-
dc.description.abstractPrimaquine can produce adverse reactions as toxicity to blood when used in the treatment of vivax malaria. This work aimed to determine methemoglobinemia in patients with vivax malaria receiving oral therapy with primaquine. Methods: Spectrophotometric quantification of methemoglobinemia and qualitative assay for glucose-6-phosphate dehydrogenase. Results: Methemoglobinemia ranged from 2.85 to 5.45% in male patients and 3.77 to 7.34% in female patients. Conclusions: A statistically significant increase in methemoglobinemia was observed following oral therapy with primaquine, with no clinical manifestations, and independent of sex and the qualitative expression of glucose-6-phosphate dehydrogenase.pt_BR
dc.description.provenanceSubmitted by Samira Prince (prince@ufpa.br) on 2011-12-14T14:15:50Z No. of bitstreams: 2 Artigo_MetemoglobinemiaPacientesMalaria.pdf: 592368 bytes, checksum: ced7fe43e528b183f09b14bab459dbfb (MD5) license_rdf: 23892 bytes, checksum: afd5dad10b1d1e6dc10c8c5d25222c7a (MD5)en
dc.description.provenanceApproved for entry into archive by Albirene Aires(albirene@ufpa.br) on 2011-12-14T14:21:00Z (GMT) No. of bitstreams: 2 Artigo_MetemoglobinemiaPacientesMalaria.pdf: 592368 bytes, checksum: ced7fe43e528b183f09b14bab459dbfb (MD5) license_rdf: 23892 bytes, checksum: afd5dad10b1d1e6dc10c8c5d25222c7a (MD5)en
dc.description.provenanceMade available in DSpace on 2011-12-14T14:21:01Z (GMT). No. of bitstreams: 2 Artigo_MetemoglobinemiaPacientesMalaria.pdf: 592368 bytes, checksum: ced7fe43e528b183f09b14bab459dbfb (MD5) license_rdf: 23892 bytes, checksum: afd5dad10b1d1e6dc10c8c5d25222c7a (MD5) Previous issue date: 2011-02en
dc.language.isoporpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectMetemoglobinapt_BR
dc.subjectPrimaquinapt_BR
dc.subjectMalária vivaxpt_BR
dc.subjectPlasmodium vivaxpt_BR
dc.titleMetemoglobinemia em pacientes com malária por Plasmodium vivax em uso oral de primaquinapt_BR
dc.title.alternativeMethemoglobinemia in patients with Plasmodium vivax receiving oral therapy with primaquinept_BR
dc.typeArtigo de Periódicopt_BR
dc.description.resumoA primaquina pode acarretar sérios eventos adversos, com destaque para a toxicidade ao sangue. O objetivo deste trabalho é determinar a metemoglobinemia de 20 pacientes com malária por Plasmodium vivax tratados com primaquina, comparando-os segundo o sexo e a expressão da glicose-6-fosfato desidrogenase. Métodos: Quantificação da metemoglobina por espectrofotometria visível e avaliação qualitativa da glicose-6-fosfato desidrogenase. Resultados: A metemoglobinemia variou de 2,85 a 5,45% nos pacientes do sexo masculino e de 3,77 a 7,34% no feminino. Conclusões: A instituição da terapia aumentou de maneira significativa os teores de metemoglobina, sem manifestação clínica evidente e independente do sexo e da atividade enzimática.pt_BR
Appears in Collections:Artigos Científicos - FARM/ICS

Files in This Item:
File Description SizeFormat 
Artigo_MetemoglobinemiaPacientesMalaria.pdf578,48 kBAdobe PDFView/Open
Show simple item record Recommend this item


This item is licensed under a Creative Commons License Creative Commons